TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06765889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: The mindfulness intervention will consist of three tracks of mindfulness practice adapted from a traditional Mindfulness-Based Stress Reduction (MBSR) protocol. The three mindfulness tracks will incorporate essential elements of mindfulness practice: a) cultivating attentional stability by directing focus to present-moment bodily experiences (Moore et al., 2012), and b) fostering mindful meta-awareness by nonreactively and nonjudgmentally observing and accepting experiences (Dahl et al., 2015).
Study: NCT05698979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX INJECTION
Description: The patient will be treated with a single session with botulinum toxin A injections at the hospital, and the judgmental criteria will be assessed at 1, 3 and 6 months post injections.~The injections will be made in 4 injection points at the palmar or distal plantar fold, at the level of the neurovascular beams, 2h after topical anesthesia by lidocaine cream under occlusion, associated or not with nitrous oxide inhaled at the time of the injections (BOTOX® 100 U).~In the event of multiple lesions, a single limb is injected based on clinical severity (ulcer, gangrene) and ischemia parameters (lowest TCPO2).
Study: NCT06765889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: The sham meditation group will aim to be indistinguishable from meditation practice for newcomers (Zeidan et al., 2015). Non-specific elements of meditation, such as a soothing instructor's voice and terminology designed to create the expectation of authentic mindfulness meditation for those unfamiliar with the practice, will be emphasized. However, the instructions will deliberately exclude the training of the two fundamental cognitive/meta-cognitive processes crucial in mindfulness practice. This intentional omission will involve 1) removing any attentional stability by providing participants with no specific point to anchor their attention and 2) offering no guidance on cultivating mindful meta-cognitive qualities of attention. Participants in the mindfulness group will be taught to observe and accept their present-moment experience without judgment or reaction. In contrast, sham instructions will provide no such guidance.
Study: NCT06768827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Oral Product
Description: Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactulose Oral Product
Description: Each arm will undergo a study to induce colonic fermentation through lactulose at the beginning and at the end of the 12 weeks.
Study: NCT05805722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling for tobacco cessation
Description: Participants can choose to receive behavioral counseling in group v. individual format:~Group Sessions: Participants will be offered the opportunity to attend 6 weekly 60-90 minute sessions Individual Sessions: Participants will be offered the opportunity to attend up to 12 30-45 minute sessions on a schedule mutually agreed upon between interventionist and participant
Study: NCT06767631

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: threedimensional freehand ultrasound and instrumented spasticity assessment
Description: To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.
Study: NCT06767319

Intervention type: OTHER
Intervention: No intervention
Description: The difference in diopters of depth of focus range achieving a threshold of 0.20 logMAR between Trial lens vs. Chart testing method per pre-study IOL group.
Study: NCT06765161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efgartigimod administration
Description: efgartigimod infusion
Study: NCT06767956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GOLCADOMIDE
Description: Golcadomide (GOLCA, CC-99282) is an oral cereblon E3 ligase modulator (CELMoD®) agent with immunomodulatory and tumor cell-autonomous activities. It is a modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint inhibitor targeted therapy drug that blocks the PD-1 (programmed death receptor-1) pathway to help prevent cancer cells from hiding from the immune system, boosting the immune system's response.
Study: NCT06767046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRAS-specific Autologous TCR-T cell injection
Description: Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection
Study: NCT06767306

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (extracranial) concurrent with immunotherapy
Description: A minimum SBRT biologically effective dose (BED) of 48Gy10 to all sites of extracranial metastatic disease should be administered between cycle 1 and cycle 3 of standard of care immunotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy alone
Description: All patients will receive standard of care 1st line immunotherapy as decided by the treating clinician and in accordance with the current listing on the Australian Register of Therapeutic Goods (ARTG) or applicable international regulatory agency.
Study: NCT06769971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: 20mg/kg，IV infusion，Day1，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: 10mg/kg，IV infusion，Day8，Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/kg，IV infusion，Day1-3，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5，IV infusion，Day1，Q3W
Study: NCT06028802

Intervention type: DIAGNOSTIC_TEST
Intervention: CT Clock Tool measurement
Description: Ratio of CT attenuation measurements acquired from within the visible ischaemic lesion (or estimated location if not visible) ÷ CT attenuation measurements acquired from within the equivalent normal brain.
Study: NCT06767592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-Kult Advanced
Description: Bio-Kult Advanced will be provided as capsules and can be stored at room temperature. Participants will be instructed to swallow two capsules in the morning and two capsules in the evening, with food.
Study: NCT06768970

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CARDIO® salmon oil
Description: CARDIO® is a natural salmon oil manufactured from the enzymatic hydrolysis of Norwegian Atlantic salmon. Salmon capsules contain a full spectrum omega- and non-omega marine fatty acids with naturally occurring astaxanthin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CARDIO® salmon oil
Description: CARDIO® is a natural salmon oil manufactured from the enzymatic hydrolysis of Norwegian Atlantic salmon. Salmon capsules contain a full spectrum omega- and non-omega marine fatty acids with naturally occurring astaxanthin.
Study: NCT06769945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Care Based on Kolcaba's Comfort Theory
Description: In practice, patient education, pain management, emotional support, appropriate environmental arrangements and individualised care come to the fore. Studies show that with this approach, patients' physical comfort increases, anxiety levels decrease and overall satisfaction improves. It is stated that nursing care based on Kolcaba's theory offers an effective model to improve the quality of life of postoperative patients.
Study: NCT06087263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given by PO
Study: NCT06366269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: traditional and electroacupuncture

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral management
Description: based on American urologic association guidelines
Study: NCT04550169

Intervention type: OTHER
Intervention: Intensive Care Coordination
Description: Intensive care coordination will include:~* Discharge instructions and contacts for following up on care and treatment~* Referral information~* Appointment scheduling~* Medication instructions~* Intensive care coordination by a social worker, case manager, nurse, or care coordinator to connect Medical Assistance (MA) recipient to a primary care provider or to a managed care organization~* Information about other health and social resources, such as transportation and housing~* Sharing of information (discharge instructions, medication information, and care plan information) with managed care organization in which patients are enrolled, if applicable
Study: NCT04858412

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: β-hydroxy β-methyl butyrate (HMB) enriched amino acid
Description: β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Balanced amino acid
Description: Balanced amino acid is the balanced mixture of the various essential amino acids.
Study: NCT06465745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AltaValve System.
Description: Transcatheter Mitral Valve Replacement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AltaValve System.
Description: Transcatheter Mitral Valve Replacement.
Study: NCT06339580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volume-targeted non-invasive ventilation
Description: A target tidal volume is set on the ventilation device, and the device will then automatically adjust delivered pressures to reach this target tidal volume.
Study: NCT05458258

Intervention type: DEVICE
Intervention: Bioelectrical Impedence Analysis Device
Description: A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.

Intervention type: DEVICE
Intervention: Bioelectrical Impedence Analysis Device
Description: A device that helps measure body composition, in particular body fat and muscle mass based on based on the rate at which an electrical current travels through the body.

Intervention type: OTHER
Intervention: 6 Minute Walk Test
Description: Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.

Intervention type: OTHER
Intervention: 6 Minute Walk Test
Description: Defined as the distance the participant is able to walk in 6 minutes. Participants will be instructed to perform laps from the 0- to 30 minutes mark and back again for a total of 6 min in an outpatient or inpatient setting on a flat, pre-defined course. Participants will be instructed that goal of the test is to walk as far as possible.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography Scans to Measure Skeletal Muscular Index
Description: Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography Scans to Measure Skeletal Muscular Index
Description: Computed tomography scans (a type of x-ray) that will measure the skeletal muscular index (the ratio of the muscle in your arms and legs to your height).

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Test/Blood Draw
Description: Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Test/Blood Draw
Description: Blood will be drawn through a need inserted into the participant's arm. This blood will be used to measure the participant's nutrition levels.

Intervention type: OTHER
Intervention: Hand Grip Strength Test
Description: Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.

Intervention type: OTHER
Intervention: Hand Grip Strength Test
Description: Grip strength in both hands will be measured using an adjustable hydraulic grip strength dynamometer (a device that is gripped to measure hand strength). The best performance of three trials will be selected for each hand, with averages of the left and right hand used in analyses.
Study: NCT05700006

Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Standard of care anastrozole, exemestane, or letrozole

Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Standard of care anastrozole, exemestane, or letrozole
Study: NCT05578586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem 1000 mg
Description: given as 6 or 3 infusions in 15 minues or 3 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem 1000 mg
Description: given as 6 or 3 infusions in 15 minues or 3 hours.
Study: NCT04302623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Upa Yoga program consisting of physical postures, breathing techniques, chanting, and meditation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Upa Yoga program consisting of physical postures, breathing techniques, chanting, and meditation.
Study: NCT05929235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-909
Description: FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX-909
Description: FX-909 is an orally available new molecular entity that inhibits basal- and ligand-activated transcription by PPARG.
Study: NCT06342089

Intervention type: OTHER
Intervention: Type I diabetes milletus
Description: the exposure is type I diabetes milletus
Study: NCT05151497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group:Halliwick + Método Watsu
Description: Carrying out the Ten Points Program through the Halliwick Concept, together with the Watsu Method through a series of relaxation maneuvers and mobilization of the body in float, and an immersion time of 15 minutes without doing physical activity in a pool at a temperature of 30ºC , to decrease spasticity of various muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group:Halliwick
Description: Exclusive use of treatment through the Halliwick Concept Ten Point Program, along with immersion in hot water to reduce spasticity in various muscles.
Study: NCT05675852

Intervention type: OTHER
Intervention: 68-electrode electroencephalography with steady state visual evoked potentials
Description: Electroencephalography is registered through a 68-electrode electroencephalography while stimuli will be presented at the centre of the screen at a distance of 150cm.~The pattern of visual stimulation is based on the technique of steady state visual evoked potentials. These potentials consist of the presentation of a visual stimulus at a (relatively fast) periodic rate to produce an EEG signal over the occipital cortex exactly at the frequency of stimulation. By varying the value of a parameter of the stimulation (e.g. the contrast of the stimulus) varies. This variation makes it possible to determine the threshold value where an EEG response is perceived, and thus to evaluate visual parameters such as visual acuity, contrast sensitivity or recognition of more complex shapes.
Study: NCT05515614

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Targeted Fortification
Description: Mother's breast milk will be fortified in modular fashion based on the level of macronutrients (protein, carbohydrate, and fat) found from analysis using the Miris Human Milk Analyser. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. Mother's breast milk will be fortified in modular fashion. For protein supplementation, Amino Acid powder will be utilized as a modular component. For carbohydrate supplementation, PolyCal will be utilized. For lipid supplementation, safflower oil will be utilized. We will set our goal energy level between 110 - 135 kcal/kg/day, protein level between 3.5 - 4.5 g/kg/day, lipid level between 4.8 - 6.6 g/kg/day, and carbohydrate level between 11.6 - 13.2 g/kg/day. We will regard daily fluid volume to be between 150 to 180 mL/kg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enfamil Liquid Human Milk Fortifier
Description: Mother's breast milk will be fortified using Enfamil Liquid Human Milk Fortifier as per standard feeding protocol defined by LLUCH NICU manual.
Study: NCT06366269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral management
Description: based on American urologic association guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: pelvic floor with biofeedback
Study: NCT03390530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thyroxine
Description: 8 µg/kg/day divided into two doses intravenous every 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05550363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexycu
Description: 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Vehicle
Description: Placebo/vehicle, 0 mcg/mcl dexamethasone: equivalent dexamethasone dose: 0 mcg
Study: NCT05636462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global postural re-education program
Description: Different postures of global re-education programs are used and stretch is applied in these postures.~3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Isometrics and stretching is used as conventional treatment. 3 sessions per week are given and each session time is 40 minutes. Treatment is given for 4 weeks.
Study: NCT06366269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: pelvic floor with biofeedback
Study: NCT05425641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Individuals will receive daily text messages that include the Goal Setting behavior change technique (BCT) with the goal of increasing daily walking by 1,000 more steps than their baseline average step count. An example of the Goal Setting BCT is Is your goal to walk an extra 1,000 steps more than your baseline average?.
Study: NCT05135546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant nonimmunogenic staphylokinase
Description: 15 mg of drug reconstituted in 6 ml of 0.9% solution of NaCl for inhalation Other Name: Fortelyzin®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 ml of 0.9% solution of NaCl for inhalation
Study: NCT06266091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M701
Description: Intra-peritoneal infusion of M701 combined with system therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracentesis
Description: paracentesis combined with system therapy
Study: NCT05176977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support-Whole Health Coaching
Description: Participants will meet with a Peer Specialist for 18 sessions over a period of 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist and 2) a structured Whole Health Coaching curriculum.
Study: NCT06319703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education and Support (DSMES) Videos
Description: Text message-delivered video-based DSMES intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Support (CHW)
Description: Assess participants' SDOH barriers to Type 2 diabetes care and link them to available resources in the community.
Study: NCT00347997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 217z Laser
Description: LASIK correction of myopia and myopic astigmatism
Study: NCT04866121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: A standardized acupuncture protocol will be administered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: A standardized acupuncture protocol will be administered
Study: NCT05377970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thinkific Prehabilitation Exercise Program
Description: Prehabilitation exercise program through the Thinkific platform
Study: NCT04757818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) in mouthwash
Description: A mouthwash and gargles with 15 ml of 0.07% cetylpyridinium chloride (CPC) in mouthwash for 1 minute.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water with the same colorant as the experimental product
Description: A mouthwash and gargles with 15 ml of distilled water for 1 minute